DYNLL1 and esophageal squamous cell carcinoma: Moreover, in a prospective cohort of treatment-naïve ESCC patients receiving radiotherapy (n=23) (Supplementary Table 9), clinical interrogation of DYNLL1-AS1 pathobiology revealed its role as a radiotherapy-responsive immunomodulator.